108 related articles for article (PubMed ID: 35519188)
21. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
Amin SA; Ghosh K; Gayen S; Jha T
J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
[TBL] [Abstract][Full Text] [Related]
22. Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs.
Hosseini M; Chen W; Xiao D; Wang C
Precis Clin Med; 2021 Mar; 4(1):1-16. PubMed ID: 33842834
[TBL] [Abstract][Full Text] [Related]
23. Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach.
Singh R; Gautam A; Chandel S; Sharma V; Ghosh A; Dey D; Roy S; Ravichandiran V; Ghosh D
In Silico Pharmacol; 2021; 9(1):27. PubMed ID: 33842191
[TBL] [Abstract][Full Text] [Related]
24. Drug repurposing using computational methods to identify therapeutic options for COVID-19.
Mahdian S; Ebrahim-Habibi A; Zarrabi M
J Diabetes Metab Disord; 2020 Dec; 19(2):691-699. PubMed ID: 32837954
[TBL] [Abstract][Full Text] [Related]
25. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.
de Oliveira OV; Rocha GB; Paluch AS; Costa LT
J Biomol Struct Dyn; 2021 Jul; 39(11):3924-3933. PubMed ID: 32448085
[TBL] [Abstract][Full Text] [Related]
26.
Gurung AB
Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
[TBL] [Abstract][Full Text] [Related]
27. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S
J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956
[TBL] [Abstract][Full Text] [Related]
28. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
[TBL] [Abstract][Full Text] [Related]
29. Polyphenols as alternative treatments of COVID-19.
Wu Y; Pegan SD; Crich D; Desrochers E; Starling EB; Hansen MC; Booth C; Nicole Mullininx L; Lou L; Chang KY; Xie ZR
Comput Struct Biotechnol J; 2021; 19():5371-5380. PubMed ID: 34567475
[TBL] [Abstract][Full Text] [Related]
30. Molecular Docking as a Potential Approach in Repurposing Drugs Against COVID-19: a Systematic Review and Novel Pharmacophore Models.
Fadlalla M; Ahmed M; Ali M; Elshiekh AA; Yousef BA
Curr Pharmacol Rep; 2022; 8(3):212-226. PubMed ID: 35381996
[TBL] [Abstract][Full Text] [Related]
31. Computational design of DNA binding domain-retained fusion proteins and virtual screening against FDA-approved drugs.
Kumar H; Kim P
bioRxiv; 2023 May; ():. PubMed ID: 37214900
[TBL] [Abstract][Full Text] [Related]
32. Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection.
Stagnoli S; Macari G; Corsi P; Capone B; Vidaurrazaga A; Ereño-Orbea J; Ardá A; Polticelli F; Jiménez-Barbero J; Abrescia NG; Coluzza I
ACS Omega; 2023 Nov; 8(46):43490-43499. PubMed ID: 38027314
[TBL] [Abstract][Full Text] [Related]
33. Pharmacophore model-aided virtual screening combined with comparative molecular docking and molecular dynamics for identification of marine natural products as SARS-CoV-2 papain-like protease inhibitors.
Thangavel N; Albratty M
Arab J Chem; 2022 Dec; 15(12):104334. PubMed ID: 36246784
[TBL] [Abstract][Full Text] [Related]
34.
El Hassab MA; Ibrahim TM; Shoun AA; Al-Rashood ST; Alkahtani HM; Alharbi A; Eskandrani RO; Eldehna WM
RSC Adv; 2021 Apr; 11(26):16026-16033. PubMed ID: 35481212
[TBL] [Abstract][Full Text] [Related]
35. Targeting SARS-CoV-2 main protease by teicoplanin: A mechanistic insight by docking, MM/GBSA and molecular dynamics simulation.
Azam F; Eid EEM; Almutairi A
J Mol Struct; 2021 Dec; 1246():131124. PubMed ID: 34305175
[TBL] [Abstract][Full Text] [Related]
36. Dieckol and Its Derivatives as Potential Inhibitors of SARS-CoV-2 Spike Protein (UK Strain: VUI 202012/01): A Computational Study.
Aatif M; Muteeb G; Alsultan A; Alshoaibi A; Khelif BY
Mar Drugs; 2021 Apr; 19(5):. PubMed ID: 33922914
[TBL] [Abstract][Full Text] [Related]
37. Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.
Kumar S; Singh B; Kumari P; Kumar PV; Agnihotri G; Khan S; Kant Beuria T; Syed GH; Dixit A
Comput Struct Biotechnol J; 2021; 19():1998-2017. PubMed ID: 33841751
[TBL] [Abstract][Full Text] [Related]
38. Targeting multiple conformations of SARS-CoV2 Papain-Like Protease for drug repositioning: An in-silico study.
Ismail MI; Ragab HM; Bekhit AA; Ibrahim TM
Comput Biol Med; 2021 Apr; 131():104295. PubMed ID: 33662683
[TBL] [Abstract][Full Text] [Related]
39. Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19).
De Vita S; Chini MG; Lauro G; Bifulco G
RSC Adv; 2020 Nov; 10(67):40867-40875. PubMed ID: 35519188
[TBL] [Abstract][Full Text] [Related]
40. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
